Food tech startup Wildtype has achieved a significant milestone by becoming the first company to receive FDA approval for its cell-cultivated salmon, marking a transformative moment for the seafood industry and alternative protein space. The cultivated salmon is now available at Portland’s Kann restaurant, with expansion plans for four more restaurants in the coming months. Wildtype’s approach involves harvesting living cells from Pacific coho salmon and cultivating them in bioreactors that replicate the natural conditions of a wild fish’s habitat. Over a four to six week production cycle, the cells grow into sushi-grade “saku” blocks, the premium cuts used for raw sushi and sashimi. The resulting product is free from mercury, antibiotics, parasites, and microplastics while retaining high levels of healthy omega-3 and omega-6 fatty acids, making it a safe and sustainable alternative to wild-caught fish. The implications are significant for overfishing, bycatch, and animal welfare, as Wildtype’s closed production system addresses many issues facing traditional fishing and aquaculture. According to Wildtype, its San Francisco pilot facility can currently produce up to 50,000 pounds of cultivated seafood annually, with plans to scale further as consumer adoption grows and more restaurants come onboard. This development places Wildtype alongside other cultivated meat pioneers like Upside Foods and Good Meat, who have gained regulatory approval for lab-grown chicken and beef. By offering a seafood option, Wildtype fills an important gap in the cell-based protein market, positioning itself as a leader in sustainable food innovation. Consumers and environmental advocates alike see this as a step toward reducing ocean depletion while satisfying the growing global demand for high-quality, safe, and environmentally responsible seafood. For more details, visit their official blog at Wildtype News and the feature by Popular Science at PopSci.